Neuralink achieves milestone with third human brain implant and plans for more trials in 2025

Neuralink has successfully implanted its third patient, marking a significant milestone in its brain-computer interface development. The company plans to conduct trials with 20 to 30 more implants this year, focusing on patients with spinal cord injuries. Since the first implant a year ago, Neuralink has improved its devices, adding more electrodes and increasing battery life. Previous recipients have demonstrated the device's capabilities by playing video games and using design software. Neuralink received FDA approval in 2023 to test its implants in humans. The company aims to enhance digital independence for patients with severe movement limitations, with future upgrades potentially benefiting healthy individuals as well.